Table 2.
Patients characteristics
| Publication, year | Arms | Age (y) | Female (%) | ASCVD (%) | DM (%) | AHT (%) | BMI (kg/m2) | CKD (%) | TC (mg/dL) | LDL-C (mg/dL) | HDL-C (mg/dL) | Non-HDL-C (mg/dL) | TG (mg/dL) | apoB (mg/dL) | hs-CRP (mg/L) |
| Ballantyne et al6, (CLEAR Tranquillity) | BA | 63.8 | 60.2 | 27.1 | 19.3 | 61.3 | 29.5 | 75.2 | 218.2 | 129.8 | 55.8 | 162.4 | 135.5 | 123.3 | 2.21 |
| Placebo | 63.7 | 63.6 | 25 | 19.3 | 58 | 30.5 | 80.7 | 208.6 | 123 | 57.1 | 151.6 | 153 | 115.8 | 2.26 | |
| Ballantyne et al7 | BA+EZE | 62.2 | 51.2 | 61.6 * | 40.7 | 86 | 31.1 | 65.1 | 237.4 | 153.9 | 49.1 | 188.3 | 156.8 | 121.1 | 3.1 |
| BA | 65 | 54.5 | 62.5 * | 51.1 | 87.5 | 30.6 | 69.3 | 225.5 | 145 | 49.9 | 175.6 | 140.8 | 113.4 | 2.9 | |
| EZE† | 65.1 | 50 | 62.8 * | 50 | 82.6 | 29.9 | 66.3 | 231.3 | 148.9 | 51.4 | 180.2 | 143.5 | 115.5 | 2.8 | |
| Placebo | 65.4 | 41.5 | 63.4 * | 41.5 | 63.4 | 30.7 | 53.6 | 231.3 | 152.8 | 50.3 | 181 | 139.1 | 115.1 | 3 | |
| Goldberg et al8, (CLEAR Wisdom) | BA | 64.1 | 37.2 | 27.1 | 29.7 | 83.9 | 30 | 79.6 | 202.1 | 119.4 | 51.4 | 150.7 | 139.3 | 116.2 | 1.61 |
| Placebo | 64.7 | 34.6 | 25.2 | 31.5 | 87.2 | 30.6 | 78.2 | 204.8 | 122.4 | 51.1 | 153.7 | 143 | 118.6 | 1.88 | |
| Gutierrez et al11 | BA | 55.3 | 43.3 | – | 100 | 26.7 | 30.6 | – | 206.3 | 125.2 | 43.7 | – | 181.5 | – | 2.3 |
| Placebo | 56 | 33.3 | – | 100 | 26.7 | 29.2 | – | 206.7 | 128.4 | 47.4 | – | 152 | – | 2.2 | |
| Laufs et al9 (CLEAR Serenity) | BA | 65.2 | 56.8 | 27.1 | 26.9 | 67.5 | 30.1 | 75.2 | 245.7 | 158.5 | 52.2 | 193.5 | 156.5 | 141 | 2.92 |
| Placebo | 65.1 | 55 | 25.3 | 23.4 | 67.6 | 30.6 | 85.6 | 241.1 | 155.6 | 50.4 | 190.7 | 164 | 141.9 | 2.78 | |
| Ray et al10 (CLEAR Harmony) | BA | 65.8 | 26.1 | 97.4 | 28.6 | 78.9 | – | – | 179.7 | 103.6 | 48.7 | 130.9 | 126 | 88.5 | 1.49 |
| Placebo | 66.8 | 28.7 | 98 | 28.6 | 80.1 | – | – | 178.6 | 102.3 | 49.3 | 129.4 | 123 | 86.8 | 1.51 |
Patient characteristics of all included trials.
*ASCVD and/or heterozygous familial Hypercholesterolemia.
†Not included in the meta analysis.
AHT, arterial hypertension; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; BA, bempedoic acid; BMI, body mass index; CKD, chronic kidney disease (estimated glomerular filtration rate <90 mL/min); DM, diabetes mellitus; EZE, ezetimibe; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; y, years.